Marigo Stathis
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Marigo Stathis has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Ajit G. Thomas
Johns Hopkins Drug Discovery, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
2 shared publications - Barbara S. Slusher
Johns Hopkins Drug Discovery, Johns Hopkins University School of Medicine, Baltimore, MD, USA
2 shared publications - Camilo Rojas
Johns Hopkins Drug Discovery, Johns Hopkins University School of Medicine, Baltimore, MD, USA
2 shared publications - Brent R. Stockwell
Department of Chemistry, Columbia University, New York, USA
1 shared publication - Huihong Zhai
Department of Gastroenterology, Xuanwu Hospital, Capital Medical University, Beijing, China
1 shared publication James J. Vornov
Medpace, Cincinnati, Ohio, USA
1 shared publication
Latest Publications
- Open Access
- 1 March 2017
- Published by Elsevier in Biochemistry and Biophysics Reports
- Vol. 9, 266-272
Development of a primary microglia screening assay and its use to characterize inhibition of system xc- by erastin and its analogs
- 1 March 2017
- Published by Elsevier in Biochemistry and Biophysics Reports
- Vol. 9, 266-272
Open AccessDevelopment of a primary microglia screening assay and its use to characterize inhibition of system xc- by erastin and its analogs
- Open Access
- 4 August 2016
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 1 (12)
FOLH1/GCPII is elevated in IBD patients, and its inhibition ameliorates murine IBD abnormalities
Recent gene-profiling analyses showed significant upregulation of the folate hydrolase ( FOLH1 ) gene in the affected intestinal mucosa of patients with inflammatory bowel disease (IBD). The FOLH1 gene encodes a type II transmembrane glycoprotein termed glutamate carboxypeptidase II (GCPII). To establish that the previously reported increased gene expression was functional, we quantified the glutamate carboxypeptidase enzymatic activity in 31 surgical specimens and report a robust 2.8- to 41-fold increase in enzymatic activity in the affected intestinal mucosa of IBD patients compared with an uninvolved area in the same patients or intestinal mucosa from healthy controls. Using a human-to-mouse approach, we next showed a similar enzymatic increase in two well-validated IBD murine models and evaluated the therapeutic effect of the potent FOLH1 /GCPII inhibitor 2-phosphonomethyl pentanedioic acid (2-PMPA) (IC 50 = 300 pM). In the dextran sodium sulfate (DSS) colitis model, 2-PMPA inhibited the GCPII activity in the colonic mucosa by over 90% and substantially reduced the disease activity. The significance of the target was confirmed in FOLH1 –/– mice who exhibited resistance to DSS treatment. In the murine IL-10 –/– model of spontaneous colitis, daily 2-PMPA treatment also significantly reduced both macroscopic and microscopic disease severity. These results provide the first evidence of FOLH1 /GCPII enzymatic inhibition as a therapeutic option for IBD.
- 4 August 2016
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 1 (12)
Open AccessFOLH1/GCPII is elevated in IBD patients, and its inhibition ameliorates murine IBD abnormalities
Recent gene-profiling analyses showed significant upregulation of the folate hydrolase ( FOLH1 ) gene in the affected intestinal mucosa of patients with inflammatory bowel disease (IBD). The FOLH1 gene encodes a type II transmembrane glycoprotein termed glutamate carboxypeptidase II (GCPII). To establish that the previously reported increased gene expression was functional, we quantified the glutamate carboxypeptidase enzymatic activity in 31 surgical specimens and report a robust 2.8- to 41-fold increase in enzymatic activity in the affected intestinal mucosa of IBD patients compared with an uninvolved area in the same patients or intestinal mucosa from healthy controls. Using a human-to-mouse approach, we next showed a similar enzymatic increase in two well-validated IBD murine models and evaluated the therapeutic effect of the potent FOLH1 /GCPII inhibitor 2-phosphonomethyl pentanedioic acid (2-PMPA) (IC 50 = 300 pM). In the dextran sodium sulfate (DSS) colitis model, 2-PMPA inhibited the GCPII activity in the colonic mucosa by over 90% and substantially reduced the disease activity. The significance of the target was confirmed in FOLH1 –/– mice who exhibited resistance to DSS treatment. In the murine IL-10 –/– model of spontaneous colitis, daily 2-PMPA treatment also significantly reduced both macroscopic and microscopic disease severity. These results provide the first evidence of FOLH1 /GCPII enzymatic inhibition as a therapeutic option for IBD.